{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:01Z","timestamp":1791389821034,"version":"4.3.3"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022880","name":"Inari Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.acvd.2023.11.007","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T17:32:03Z","timestamp":1700760723000},"page":"101-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cancer-related arterial thromboembolic events"],"prefix":"10.1016","volume":"117","author":[{"given":"Gilles","family":"Pernod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2023.11.007_bib0435","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.16.00071","article-title":"Visualization of cancer and cardiovascular disease co-occurrence with network methods","volume":"1","author":"Duarte","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.acvd.2023.11.007_bib0445","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/rth2.12223","article-title":"The risk of arterial thromboembolic events after cancer diagnosis","volume":"3","author":"Navi","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.007_bib0450","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0455","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial thromboembolism in cancer\u00a0patients: a danish population-based cohort study","volume":"3","author":"Mulder","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0460","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2011.09.015","article-title":"Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acvd.2023.11.007_bib0465","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2012.01.005","article-title":"Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden","volume":"48","author":"Zoller","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acvd.2023.11.007_bib0470","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.acvd.2023.11.007_bib0475","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12885-020-06838-w","article-title":"Cardiovascular disease events within 5 years after a diagnosis of breast cancer","volume":"20","author":"Mery","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.acvd.2023.11.007_bib0480","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/COC.0000000000000904","article-title":"Cardiovascular diseases following breast cancer: towards a case-by-case assessment through a prediction risk score model in 943 patients","volume":"45","author":"Mery","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0485","first-page":"211","article-title":"Arterial thrombo-embolism in patients with cancer: frequency, risk factors and mortality","volume":"1","author":"Grilz","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.007_bib0490","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0495","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113642","article-title":"Characteristics, management and outcomes of acute coronary syndrome patients with cancer","volume":"9","author":"Milazzo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0500","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.acvd.2019.06.012","article-title":"In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: results from the French registry on acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort","volume":"112","author":"Ederhy","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.007_bib0505","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1161\/STROKEAHA.111.615534","article-title":"Lung cancer and incidence of stroke: a population-based cohort study","volume":"42","author":"Chen","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2023.11.007_bib0510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1741-7015-12-53","article-title":"Risk of ischemic stroke in patients with ovarian cancer: a nationwide population-based study","volume":"12","author":"Kuan","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0515","doi-asserted-by":"crossref","first-page":"e1336","DOI":"10.1097\/MD.0000000000001336","article-title":"Risk of ischemic stroke in patients with gastric cancer: a nationwide population-based cohort study","volume":"94","author":"Kuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acvd.2023.11.007_bib0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke","volume":"77","author":"Navi","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0525","doi-asserted-by":"crossref","first-page":"e2025","DOI":"10.1212\/WNL.0000000000005636","article-title":"New diagnosis of cancer and the risk of subsequent cerebrovascular events","volume":"90","author":"Navi","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2023.11.007_bib0530","doi-asserted-by":"crossref","first-page":"966190","DOI":"10.3389\/fneur.2022.966190","article-title":"Incidence of stroke in the first year after diagnosis of cancer - a systematic review and meta-analysis","volume":"13","author":"Lun","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0535","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.acvd.2023.11.007_bib0540","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11060-012-1011-4","article-title":"Clinical manifestation of cancer related stroke: retrospective case-control study","volume":"111","author":"Kim","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0545","doi-asserted-by":"crossref","first-page":"107154","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107154","article-title":"Stroke as a cause of death in patients with cancer: a SEER-based study","volume":"32","author":"Sonbol","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.007_bib0550","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/23969873231151488","article-title":"Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: prevalence, treatment, and clinical implications - the PLEURA study","volume":"8","author":"Dittrich","year":"2023","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0555","doi-asserted-by":"crossref","first-page":"e013215","DOI":"10.1161\/JAHA.119.013215","article-title":"Prevalence and impact of venous and arterial thromboembolism in patients with embolic stroke of undetermined source with or without active cancer","volume":"8","author":"Ha","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2023.11.007_bib0560","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial ischemic events are a major complication in cancer patients with venous thromboembolism","volume":"131","author":"Brenner","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0565","article-title":"Bridging the gap in cancer-related stroke management: update on therapeutic and preventive approaches","volume":"24","author":"Sun","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.acvd.2023.11.007_bib0570","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2017.05.006","article-title":"Cancer, atrial fibrillation, and stroke","volume":"155","author":"Fitzpatrick","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0575","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.avsg.2011.06.002","article-title":"Acute limb ischemia in cancer patients: should we surgically intervene?","volume":"25","author":"Tsang","year":"2011","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0580","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2021.05.028","article-title":"External applicability of the COMPASS and VOYAGER-PAD trials on patients with symptomatic lower extremity artery disease in France: the COPART registry","volume":"62","author":"Lap\u00e9bie","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0585","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jvs.2015.06.223","article-title":"Frequency of cancer in patients operated on for acute peripheral arterial thrombosis and the impact on prognosis","volume":"62","author":"Nicolajsen","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0590","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jvs.2021.03.058","article-title":"A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer","volume":"74","author":"Govsyeyev","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0595","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejvs.2007.08.014","article-title":"Arterial thrombosis associated with malignant disease","volume":"35","author":"Javid","year":"2008","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0600","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijsu.2010.01.007","article-title":"Surgical treatment of acute limb ischaemia in the presence of malignancy","volume":"8","author":"Morris-Stiff","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0605","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/bjs.5125","article-title":"Association of malignant disease with critical leg ischaemia","volume":"92","author":"El Sakka","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.acvd.2023.11.007_bib0610","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0615","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.acvd.2023.02.005","article-title":"Atrial fibrillation, cancer and anticancer drugs","volume":"116","author":"Font","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2023.11.007_bib0620","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jaccao.2022.11.019","article-title":"Atrial Fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials","volume":"5","author":"Alexandre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0625","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11739-022-03156-w","article-title":"Bleeding and thrombotic events in atrial fibrillation patients with cancer: a systematic review and meta-analysis","volume":"18","author":"Pastori","year":"2023","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0630","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","article-title":"Arterial Thromboembolism in Patients With AF and CHA(2)DS(2)-VASc Score 0-2 with and without cancer","volume":"5","author":"Leader","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0635","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis","volume":"43","author":"Guha","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0640","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2023.11.007_bib0655","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0660","first-page":"12","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of cml: a meta-analysis","author":"Haguet","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acvd.2023.11.007_bib0665","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"Moik","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0645","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.acvd.2023.11.007_bib0650","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0670","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.1991.9.2.286","article-title":"Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer","volume":"9","author":"Saphner","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0675","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20,000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2023.11.007_bib0680","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.acvd.2023.11.007_bib0685","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00228-010-0988-x","article-title":"Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials","volume":"67","author":"Hang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0690","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0695","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0700","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2014.04.004","article-title":"Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis","volume":"92","author":"Qi","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0705","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdr592","article-title":"Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials","volume":"23","author":"Petrelli","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0710","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3389\/fphar.2020.01007","article-title":"The risk of arterial thrombosis in patients with chronic myeloid leukemia treated with second and third generation BCR-ABL tyrosine kinase inhibitors may be explained by their impact on endothelial cells: an in-vitro study","volume":"11","author":"Haguet","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0715","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0720","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0725","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2023.11.007_bib0730","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0735","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.thromres.2021.02.028","article-title":"Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: a systematic review","volume":"208","author":"Frere","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0740","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.3390\/curroncol30030230","article-title":"Immune checkpoint inhibitors-associated thrombosis: incidence, risk factors and management","volume":"30","author":"Wang","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0745","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0750","first-page":"101056","article-title":"French guidelines for the treatment of cancer-associated venous thromboembolism - 2023 update","volume":"84","author":"Mahe","year":"2023","journal-title":"Respir Med Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0755","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0760","first-page":"947","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.acvd.2023.11.007_bib0765","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11936-023-00982-9","article-title":"Coronary revascularization in patients with cancer","volume":"25","author":"Pushparaji","year":"2023","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0770","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0775","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2017.11.29","article-title":"Temporal trends and outcomes of acute myocardial infarction in patients with cancer","volume":"5","author":"Pothineni","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0780","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12872-020-01352-0","article-title":"Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and\/or percutaneous coronary intervention","volume":"20","author":"Roule","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.acvd.2023.11.007_bib0785","first-page":"E202","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.acvd.2023.11.007_bib0790","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STROKEAHA.118.022606","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2023.11.007_bib0795","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11164696","article-title":"Mechanical thrombectomy for acute ischemic stroke in patients with malignancy: a systematic review","volume":"11","author":"Aloizou","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.acvd.2023.11.007_bib0800","first-page":"4795","article-title":"Efficacy and safety of intravenous thrombolysis for acute ischemic stroke in cancer patients: a systemic review and meta-analysis","volume":"12","author":"Huang","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.acvd.2023.11.007_bib0805","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.acvd.2023.11.007_bib0810","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs. aspirin in patients with cancer and ischemic stroke: The TEACH Pilot randomized clinical trial","volume":"75","author":"Navi","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0815","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial","volume":"27","author":"Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0820","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11886-021-01604-1","article-title":"Stroke prevention after cryptogenic stroke","volume":"23","author":"Ibeh","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.acvd.2023.11.007_bib0825","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jacc.2023.07.025","article-title":"Antithrombotic therapy for primary and secondary prevention of ischemic stroke: JACC\u00a0state-of-the-art review","volume":"82","author":"Greco","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2023.11.007_bib0830","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5853\/jos.2016.00570","article-title":"Hypercoagulability and mortality of patients with stroke and active cancer: The OASIS-CANCER study","volume":"19","author":"Lee","year":"2017","journal-title":"J Stroke"},{"key":"10.1016\/j.acvd.2023.11.007_bib0835","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0840","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2023.11.007_bib0845","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jth.14478","article-title":"Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH","volume":"17","author":"Delluc","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.acvd.2023.11.007_bib0850","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"Mariani","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.acvd.2023.11.007_bib0855","doi-asserted-by":"crossref","first-page":"e012540","DOI":"10.1161\/JAHA.119.012540","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Deng","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2023.11.007_bib0860","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.3390\/jcm11154452","article-title":"Treatment options in AF patients with cancer; focus on catheter ablation","volume":"11","author":"Garibaldi","year":"2022","journal-title":"J Clin Med"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213623005168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213623005168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:49:28Z","timestamp":1761745768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213623005168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1875213623005168"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2023.11.007","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-related arterial thromboembolic events","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2023.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}